Overview of Detrusitol SR

What is Detrusitol SR? Overview

Property	Description
Active ingredient	Tolterodine tartrate
Form	Prolonged-release hard capsule (SR/ER)
Pharmacological class	Antimuscarinic agent
Common use	Management of overactive bladder symptoms
Origin	Synthetic compound

What Type of Medicine is Detrusitol SR?

Detrusitol SR, which contains the active ingredient Tolterodine tartrate, is a prescription-only pharmaceutical preparation officially classified as an antimuscarinic agent. This medicine is a synthetic compound designed to interact specifically with certain nervous system receptors. The drug's core function is to block the action of the neurotransmitter acetylcholine at muscarinic receptors, particularly those located on the detrusor muscle (the bladder wall). This mechanism interrupts the nervous signals that trigger sudden, unprompted muscle contractions, which is the root cause of bladder over-activity.

Composition and Form: The Prolonged-Release Capsule

The sole active ingredient in Detrusitol SR is Tolterodine tartrate, and the medicine is formulated exclusively as a prolonged-release hard capsule, designated by the suffix “SR” or “Extended-Release” (ER). This specialized dosage form is intended for oral administration and differs significantly from immediate-release formulations; the capsule contains the single active ingredient alongside pharmaceutical excipients such as sucrose and maize starch that control its dissolution. This prolonged-release mechanism is a deliberate design choice, allowing the therapeutic benefit to be sustained consistently over a full day.

General Therapeutic Purpose of Tolterodine

The general purpose of Detrusitol SR is to alleviate symptoms associated with an overactive bladder by promoting the muscle relaxation of the bladder wall. The pharmacological action of inhibiting bladder contraction helps to increase the bladder's functional capacity. This results in the reduction of involuntary bladder signals, which helps address concerns such as sudden, intense urinary urgency and the frequent need to urinate throughout the day and night. Tolterodine is clinically recognized for effectively managing these persistent symptoms.

Regulatory References

Tolterodine - LiverTox - NCBI Bookshelf - NIH

What side effects are possible with Detrusitol SR?

Possible side effects and safety information

The official safety profile for Detrusitol SR (Tolterodine tartrate) is documented according to government regulatory standards, which classifies potential adverse effects by frequency and system-organ class. These classifications reflect the medicine's antimuscarinic action.

Documented Adverse Reactions

The most frequently reported adverse reaction in clinical studies is dry mouth, which is classified as Very Common. Other effects classified as Common include headache, dizziness, somnolence, constipation, abdominal pain, dyspepsia, dry eyes, and dysuria (difficult or painful urination).

Reactions classified as Uncommon include palpitations, urinary retention, chest pain, and memory impairment. These effects primarily relate to the gastrointestinal, nervous, and ocular systems, consistent with the official safety grouping.

Serious Safety Considerations

Post-marketing surveillance has documented rare but serious reactions such as Anaphylactoid reactions and Angioedema (swelling of the face, lips, or throat). The regulatory safety framework also establishes explicit restrictions and limitations. For instance, the use of Detrusitol SR is contraindicated in patients with conditions such as Urinary retention, Gastric retention, and Uncontrolled narrow-angle glaucoma.

Safety notes for specific populations include a recommendation for caution and potential adjustment for individuals with severe renal impairment and general avoidance for those with severe hepatic impairment. Certain effects, such as central nervous system reactions, are noted to require monitoring, particularly when treatment is initiated or the dose is increased.

Overdose and Emergency Response

Overdose: When to Seek Immediate Help

The following information is derived strictly from official government regulatory documents (e.g., FDA, EMA) concerning overdose and emergency response for Detrusitol SR (tolterodine).

Documented Overdose Manifestations

Overdosage with tolterodine has been observed to result in symptoms that are an exaggeration of its known pharmacological effects, specifically antimuscarinic effects. These symptoms include:

Ocular/Vision Issues: Accommodation disturbances.
Urinary Difficulties: Micturition difficulties (issues with urination).
Central Nervous System (CNS) Effects: Potential for severe central antimuscarinic effects (e.g., hallucinations, severe excitation).

In studies of the immediate-release formulation at supratherapeutic doses, an increase in the QT-interval (a measure of cardiac electrical activity) was also observed.

Immediate Actions and Management

If an overdose is suspected, immediate medical attention is required due to the risk of severe complications, particularly severe CNS effects and cardiac changes. Regulatory guidance dictates that standard supportive measures for managing symptoms and QT-prolongation should be adopted.

Specific official management procedures include:

Decontamination: Gastric lavage and the administration of activated charcoal.
Targeted Symptom Management: The use of physostigmine for severe central anticholinergic effects and beta-blockers for tachycardia.
Life Support: Artificial respiration for respiratory insufficiency and catheterization for urinary retention.

Note: All overdose statements and management protocols are based solely on information provided in official government-authorized prescribing documentation and public assessments.

Therapeutic Uses of Detrusitol SR

Detrusitol SR (Tolterodine tartrate) is commonly used across conditions characterized by periods of heightened symptoms of overactive bladder syndrome, where supportive symptom management is appropriate. It is considered relevant in clinical settings marked by the distressing presence of uncontrolled bladder activity. The medication is used to help with symptoms related to overactive bladder syndrome, including urge urinary incontinence, urgency, and frequency.

Controlling Distressing Symptoms

This medicine is applied in addressing symptom clusters that may become intense or disruptive, primarily the sudden, compelling need to pass urine (urgency) and the abnormally frequent need to void throughout the day and night. It provides support that helps ease the overall symptom burden and may assist with easing the noticeable physiological strain related to the recurrent need to find a restroom.

“This approach is relevant when symptoms become temporarily overwhelming, and supportive symptom management is deemed appropriate.”

Detrusitol SR is relevant for easing symptoms related to heightened physiological activity, specifically the involuntary loss of urine, or urge incontinence. Applied in scenarios where additional management of discomfort is required, it may assist with improving day-to-day comfort during symptomatic periods. The supportive relief provided may contribute to maintaining a sense of stability when symptoms are more noticeable, which may assist in supporting general well-being during symptomatic phases.

Quick Fact: Relief for Urgency and Frequency
Is used for managing symptoms that interfere with daily comfort and create noticeable physiological strain.

Regulatory References

NIH DailyMed Overview of Tolterodine Tartrate

Eligibility and Restrictions for Use

Who Can and Cannot Use Detrusitol SR?

Eligibility for Detrusitol SR (tolterodine extended-release) is strictly determined by regulatory labeling, which defines several groups for whom the medicine is contraindicated or not recommended.

Contraindicated Populations

Detrusitol SR must not be used by individuals with:

Urinary Retention or Gastric Retention.
Uncontrolled Narrow-Angle Glaucoma.
Known Hypersensitivity to tolterodine or its components.
Severe Ulcerative Colitis or Toxic Megacolon.

Restricted or Not Recommended Use

Use is not recommended in several key populations:

Pediatric Patients (children and adolescents), as efficacy and safety have not been established.
Pregnancy and Lactation (should be avoided).
Severe Hepatic Impairment (Child-Pugh Class C) or Severe Renal Impairment (creatinine clearance < 10 mL/min).

Patients with mild to moderate hepatic impairment or severe renal impairment (10-30 mL/min) are eligible, but the labeling mandates a reduced dosage for safe use. Caution is also required for individuals with specific heart conditions or gastrointestinal obstructive disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Detrusitol SR (tolterodine) is metabolized by the liver enzymes CYP2D6 and CYP3A4. Interactions are possible with other medicines that inhibit these enzymes, particularly CYP3A4 inhibitors.

Interacting Product Category	Examples of Medicines	Recommended Action/Note
Potent CYP3A4 Inhibitors	Ketoconazole, Erythromycin, Clarithromycin, Itraconazole, Ritonavir	Dose Reduction Required to 2 mg once daily. Concomitant use significantly increases tolterodine plasma concentration, especially in poor metabolizers.
QT-Prolonging Antiarrhythmics	Quinidine, Procainamide (Class IA); Amiodarone, Sotalol (Class III)	Use with Caution. Detrusitol SR may have a greater effect on the QT interval at higher exposure, which can be additive with other QT-prolonging drugs.
Other Antimuscarinics	Certain medications for Parkinson's or allergies, and other OAB drugs	Use with Caution. Concomitant use may result in additive antimuscarinic effects, potentially increasing side effects like dry mouth or constipation.
Cholinergic Agents	Medicines with opposite effects	Use with Caution. Potential for pharmacodynamic antagonism.
Gastro-intestinal Motility Agents	Metoclopramide, Cisapride	Use with Caution. Detrusitol SR may decrease GI motility; caution is advised with other agents that affect food passage.

No dose adjustment is required when Detrusitol SR is co-administered with Fluoxetine (a potent CYP2D6 inhibitor), Warfarin, or combined oral contraceptives (ethinyl estradiol/levonorgestrel), as these combinations were not found to result in clinically significant interactions.

Mechanism of Action

How Detrusitol SR Works: Mechanism of Action

Muscarinic Receptor Antagonism in the Detrusor Muscle

The drug Tolterodine and its active component, 5-Hydroxymethyl tolterodine (5-HMT), function as competitive antagonists by blocking the binding sites of muscarinic cholinergic receptors located on the detrusor muscle. This core mechanism directly prevents the neurotransmitter acetylcholine from binding to the receptors, thereby inhibiting the initiation of smooth muscle contraction.

Modulation of Parasympathetic Signaling and Bladder Capacity

By interrupting the parasympathetic nerve pathway, this mechanism dampens the cholinergic signaling that mediates detrusor smooth muscle contraction. The resulting physiological effect is a reduction in detrusor muscle tone and an increase in the volume the bladder can hold.

Sustained Action via Active Metabolite

The body metabolizes Tolterodine into 5-Hydroxymethyl tolterodine, a compound that works through the identical antimuscarinic blockade mechanism as the parent drug. The combined activity of both the drug and its active metabolite provides a sustained blockade of the detrusor muscle signal over time.

Dosage and Administration Information

How to Use Detrusitol SR: Official Administration Guidelines

Detrusitol SR (tolterodine tartrate extended-release capsules) is an oral medication with specific administration guidelines.

Administration Scope

The approved route for this medicine is oral administration. The prolonged-release hard capsule is available in strengths of 2 mg and 4 mg.

Dosing Schedule (Adults)	Official Instructions
Standard Daily Dose	4 mg once daily
Adjusted Daily Dose	2 mg once daily (for specific patient populations)

The capsule is designed to be taken once daily, and the therapeutic effect of treatment is subject to re-evaluation after a standard course of 2 to 3 months to determine the necessity of continued use.

Procedural and Contextual Instructions

The integrity of the prolonged-release capsule is critical for its function. The capsule must be swallowed whole with water and should not be chewed, crushed, or opened. The timing of intake is flexible, as the capsule may be administered with or without food.

Special Use-Context Constraints	Required Dose Adjustment
Severe renal or hepatic impairment	2 mg once daily
Concomitant use of potent CYP3A4 inhibitors	2 mg once daily
Missed dose	Skip the dose; do not take a double dose

Use of this medicine is not recommended for pediatric patients. Consistent adherence to the once-daily schedule and maintaining the capsule's integrity defines the correct procedural structure for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical Efficacy Studies

One body of evidence focused on the drug's effect in patients with musculoskeletal pain. These studies evaluated whether the drug was associated with changes in symptoms over a 4-week period. Follow-up studies examined the duration of observed change over a 6-month period.

Research explored the drug's use in both acute settings, such as post-operative dental pain, and chronic settings, including osteoarthritis. In trials for acute pain, studies examined the onset of effect.

Studies assessed outcomes using instruments like the Visual Analog Scale (VAS) for pain severity and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale for functional improvement.

Drug Combinations

Research evaluated the drug's effect when administered alongside a common muscle relaxant. Studies examined whether the combination was associated with better patient outcomes and whether the incidence of reported side effects increased. Early findings reported on recovery time in these combination trials.

Dose Regimens Studied

Several trials investigated various dosing regimens. Research evaluated whether the drug was associated with a change in the severity of symptoms at dosages of 100 mg, 200 mg, and 400 mg daily. The 200 mg dosage included in the study was analyzed alongside the 100 mg dosage and the 400 mg dosage; the 400 mg dosage did not show significantly different results on the primary outcome measure compared to 200 mg.

Safety and Tolerability Profile

Studies collected data on specific adverse events, including gastrointestinal side effects (e.g., dyspepsia) and cardiovascular events (e.g., hypertension). Reported adverse events were evaluated in comparison to placebo groups and groups receiving an older-generation non-steroidal anti-inflammatory drug (NSAID).

Research reviewed the incidence of reported side effects when the drug was co-administered with certain anticoagulant medications. The frequency of reported adverse events was analyzed across various patient populations, including those with pre-existing kidney or liver conditions.

Frequently Asked Questions (FAQ)

Common questions about Detrusitol SR (FAQ)

Q: Why is Detrusitol SR called an SR capsule?

A: The SR in the name stands for Sustained Release or Extended Release. This formulation is a type of dosage designed to release the active medicine slowly and consistently over a full 24-hour period. This prolonged action supports the once-per-day schedule described in official product information.

Q: Does Detrusitol SR affect your eyes or vision?

A: Official safety documents list dry eyes as a common adverse effect. Additionally, effects on the visual system, such as blurred vision and disturbances in the ability of the eye to focus (abnormal accommodation), are also noted as possible effects in the medicine's official safety profile.

Q: Does Detrusitol SR interact with alcohol?

A: Regulatory information indicates that combining the medicine with alcohol may heighten some central nervous system effects. This could potentially increase feelings of drowsiness or dizziness associated with the medicine.

Q: Is Detrusitol SR a bladder muscle relaxer?

A: The medicine is a type of antimuscarinic agent that works by blocking signals to the detrusor muscle (the bladder wall). This action reduces muscle tone, which in turn increases the bladder's capacity to hold urine.

Q: What kind of studies support the use of Detrusitol SR?

A: The medicine’s approval is supported by clinical trials that measured outcomes related to overactive bladder symptoms. These studies typically assessed key measures such as the change in the number of urinary incontinence episodes per week and the number of times a person urinates per 24 hours, comparing results to a placebo.

Q: Does research show a difference in side effects between SR and immediate-release forms?

A: The extended-release (SR) formulation is designed with the intent to reduce peak drug concentrations in the blood. Regulatory submissions for the SR form have noted potential for a reduced incidence of certain side effects, such as dry mouth, compared to the immediate-release form.

Q: How quickly does Detrusitol SR start to work?

A: Detrusitol SR is an extended-release capsule, meaning the active ingredient is released slowly to provide a sustained effect. The extended-release design helps maintain a steady concentration throughout the day, which supports continuous symptom control.

Q: How long does Detrusitol SR stay in your system?

A: The active substance takes several hours to be eliminated from the body. The prolonged-release design of the capsule is engineered to ensure the therapeutic benefits are maintained consistently over a 24-hour period.

Q: Can Detrusitol SR be taken by men?

A: Yes. The medicine is indicated for the treatment of overactive bladder symptoms in all adults, regardless of gender. Clinical trial data used to establish the safety and efficacy of the drug included both male and female patients.

Q: Does Detrusitol SR help with nighttime urination (nocturia)?

A: Official therapeutic indications state that the medicine is for treating the symptoms of overactive bladder, which includes the increased urge to urinate at night (nocturia). The once-daily, prolonged-release formulation is designed to support continuous symptom control.

Q: Do you have to take Detrusitol SR forever?

A: According to official guidelines, the necessity of continuing treatment is subject to regular review. Treatment is typically evaluated after a standard course of two to three months to determine the need for continued use.

Q: Can I stop taking Detrusitol SR without talking to a doctor?

A: Regulatory guidance states that the decision to stop or interrupt treatment should be made in consultation with a healthcare professional, as the medicine is intended to be taken as prescribed.

Q: Can you take Detrusitol SR with high blood pressure medicine?

A: Regulatory documents do not list all high blood pressure medicines as a contraindicated class. However, the official warning requires caution with medicines that affect heart rhythm (such as those that may cause QT prolongation) or those with additive antimuscarinic effects.

Q: Does Detrusitol SR affect driving?

A: Official warnings state that the medicine may cause visual changes (such as accommodation disturbances) and can influence reaction time. Official documentation states that these effects may impair the ability to drive or operate machinery.

Q: Is there a link between Detrusitol SR and cognitive issues in the elderly?

A: The official safety profile lists memory impairment as an uncommon adverse effect. The class of medicines to which Detrusitol SR belongs is associated with central nervous system effects, and the official safety profile advises monitoring for cognitive changes.

Q: Why do some people switch from immediate-release tolterodine to Detrusitol SR?

A: The extended-release capsule was developed to offer the convenience of once-daily dosing, replacing the multiple daily doses required for the immediate-release form. The sustained release of the drug is intended to reduce fluctuations in blood levels and potentially improve the tolerability of the medicine.

Q: What is the long-term safety profile of Detrusitol SR?

A: The overall safety profile is established using data collected from standard clinical trials, longer-term extension studies (up to 12 months), and ongoing post-marketing surveillance. This information informs regulatory bodies and is continuously reviewed.

Q: Does the medicine come in other strengths besides 4 mg?

A: Yes, according to official prescribing information, the medicine is available in both 2 mg and 4 mg prolonged-release hard capsules.

Q: Are there generic versions of Detrusitol SR available?

A: Approved generic versions containing tolterodine tartrate extended-release may be available, depending on the regulatory region.

Q: Can Detrusitol SR affect my sleep?

A: The official side effect list includes somnolence (drowsiness) as a common adverse effect, which can potentially interfere with sleep patterns. The medicine is also indicated for treating overactive bladder symptoms that are known to disrupt sleep.

Q: Is Detrusitol SR a controlled substance?

A: No. Tolterodine tartrate is generally not scheduled or classified as a controlled substance by major regulatory authorities.

Q: Does taking Detrusitol SR affect fertility?

A: Regulatory information indicates that studies in animals have shown reproductive toxicity. However, there is insufficient human data available to draw conclusions about the effect of tolterodine on human fertility.

Q: Are there specific warnings for women taking Detrusitol SR?

A: Official documentation states that the medicine is not recommended for use during pregnancy and is generally avoided during lactation (breastfeeding). This is based on a lack of adequate human data, though animal studies have shown reproductive toxicity.

Q: Does Detrusitol SR interact with common supplements like cranberry or magnesium?

A: The official documentation focuses primarily on interactions with prescription medicines. General guidance may caution against taking the medicine with certain herbal remedies and supplements that have not been clinically tested for interactions or that may intensify antimuscarinic side effects like dry mouth or drowsiness.

Q: Can people with stomach issues like colitis take Detrusitol SR?

A: Official prescribing information states that the medicine is contraindicated and must not be used by individuals with severe gastrointestinal conditions, specifically Severe Ulcerative Colitis or Toxic Megacolon.

Q: What if I have an allergic reaction to Detrusitol SR?

A: Documented serious allergic reactions include anaphylaxis and angioedema (swelling of the face, lips, or throat). Regulatory documents state that if a patient experiences signs of a serious reaction, the medicine should be discontinued and emergency medical treatment must be sought immediately.

Q: Is there an age limit for taking Detrusitol SR?

A: The medicine is not recommended for use in pediatric patients (children and adolescents). This is because the safety and effectiveness of the medicine have not been officially established for this population.

Q: Does Detrusitol SR affect my heart rate?

A: The official safety profile lists palpitations (a fluttering or irregular heartbeat) as an uncommon side effect. Official warnings specify that caution is required for patients with pre-existing heart conditions or known risk factors for QT prolongation (a change in the heart's electrical rhythm).

Q: Can Detrusitol SR be opened and sprinkled on food?

A: The prolonged-release capsule is designed to be swallowed whole with water. Official procedural instructions require that the capsule not be opened, crushed, or chewed because doing so interferes with the extended-release mechanism.

Q: What is the risk of having a serious side effect from Detrusitol SR?

A: In regulatory clinical trials, the incidence of serious adverse events was generally similar in patients taking the medicine and those taking a placebo. Serious, though rare, documented reactions include anaphylaxis and angioedema.

How should Detrusitol SR be stored and disposed of?

Storage Requirements

Detrusitol SR (tolterodine tartrate extended-release capsules) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed in a location protected from light, excess heat, and moisture; storage in the bathroom is prohibited.

Child Safety

To prevent accidental exposure, the medication must be kept out of reach of children and secured in a safe, high-up location. Since many drug containers are not child-resistant, safety caps must always be locked.

Disposal Instructions

Disposal must strictly adhere to federal, state, and local regulations. To safeguard the environment, the medication must not be discharged into drains or sewers. When discarding, ensure the product is placed away from children's reach.

Detrusitol SR